Advertisement
Canada markets open in 2 hours 49 minutes
  • S&P/TSX

    23,027.15
    +245.72 (+1.08%)
     
  • S&P 500

    5,471.05
    +62.63 (+1.16%)
     
  • DOW

    40,829.59
    +484.18 (+1.20%)
     
  • CAD/USD

    0.7370
    -0.0007 (-0.09%)
     
  • CRUDE OIL

    67.98
    -0.73 (-1.06%)
     
  • Bitcoin CAD

    77,540.74
    +2,384.36 (+3.17%)
     
  • XRP CAD

    0.73
    +0.01 (+1.31%)
     
  • GOLD FUTURES

    2,535.50
    +2.80 (+0.11%)
     
  • RUSSELL 2000

    2,097.78
    +6.37 (+0.30%)
     
  • 10-Yr Bond

    3.6970
    -0.0130 (-0.35%)
     
  • NASDAQ futures

    18,652.25
    -40.00 (-0.21%)
     
  • VOLATILITY

    19.90
    +0.45 (+2.31%)
     
  • FTSE

    8,227.97
    -42.87 (-0.52%)
     
  • NIKKEI 225

    36,159.16
    -56.59 (-0.16%)
     
  • CAD/EUR

    0.6677
    -0.0003 (-0.04%)
     

STAAR Surgical Second Quarter 2024 Earnings: EPS: US$0.15 (vs US$0.13 in 2Q 2023)

STAAR Surgical (NASDAQ:STAA) Second Quarter 2024 Results

Key Financial Results

  • Revenue: US$99.0m (up 7.3% from 2Q 2023).

  • Net income: US$7.38m (up 22% from 2Q 2023).

  • Profit margin: 7.5% (up from 6.6% in 2Q 2023). The increase in margin was driven by higher revenue.

  • EPS: US$0.15 (up from US$0.13 in 2Q 2023).

earnings-and-revenue-growth
earnings-and-revenue-growth

All figures shown in the chart above are for the trailing 12 month (TTM) period

STAAR Surgical Earnings Insights

Looking ahead, revenue is forecast to grow 14% p.a. on average during the next 3 years, compared to a 8.2% growth forecast for the Medical Equipment industry in the US.

Performance of the American Medical Equipment industry.

The company's shares are up 1.0% from a week ago.

Risk Analysis

You should learn about the 1 warning sign we've spotted with STAAR Surgical.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.